Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 11 art units • 21 examiners • 0 of 22 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
MEDIMMUNE Limited shows a significant level of activity in the Biotechnology & Pharmaceuticals technology area with 22 pending office actions. The portfolio is highly decentralized, as these actions are handled by 21 distinct examiners. This near-one-to-one ratio of actions to examiners suggests a very broad exposure across the patent office's personnel. Furthermore, the workload is spread across 11 distinct art units, reflecting the complex and multifaceted nature of the company's pharmaceutical and biotechnological developments.
The busiest examiner, BRISTOL, LYNN ANNE, is currently managing 2 pending office actions, which represents only a fraction of the 22 total pending actions. This distribution indicates that the company's prosecution success is not dependent on the favor of a single examiner. With 11 distinct art units involved, the portfolio must adhere to a wide array of technical and legal standards. The high number of 21 distinct examiners means that practitioners must be prepared for diverse feedback and varying levels of scrutiny across the entire pending portfolio.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (9%) |
| §103 only | 2 (9%) |
| §112 only | 5 (23%) |
| Double-patenting + other | 8 (36%) |
| Multi-statute (no §101) | 5 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001637 | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPEUTIC | SWIFT, CANDICE LEE | 28d overdue |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — |
| 18253665 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | ALLEN, MARIANNE P | — |
| 18630379 | Optimized CD3 Antigen Binding Domains | GUSTILO, ESTELLA M | — |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | WEN, SHARON X | — |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | XIAO, YAN | 33d |
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | PUTTLITZ, KARL J | — |
| 18572300 | COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATES | PETERS, ALEC JON | — |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | CHERNYSHEV, OLGA N | — |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | OUSPENSKI, ILIA I | — |
| 18287240 | AN ANTI-TSLP FAB WITH IMPROVED STABILITY | KIM, YUNSOO | — |
| 18257756 | POLYPEPTIDES AND USES THEREOF | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 4 |
| 1642 | 2 |
| 1641 | 2 |
| 1647 | 2 |
| 1675 | 1 |
| 1654 | 1 |
| 1646 | 1 |
| 1683 | 1 |
| 1631 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836305 | GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | BRADLEY, CHRISTINA | — | §101§102§103DP | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | PUTTLITZ, KARL J | 1642 | §112DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18572300 | COMBINATION THERAPY USING ANTIBODY-DRUG CONJUGATES | PETERS, ALEC JON | — | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | CHERNYSHEV, OLGA N | 1675 | §102§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18490856 | ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS | OUSPENSKI, ILIA I | — | §112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287240 | AN ANTI-TSLP FAB WITH IMPROVED STABILITY | KIM, YUNSOO | 1641 | §102§112DP | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18257756 | POLYPEPTIDES AND USES THEREOF | HELLMAN, KRISTINA M | 1654 | §112Other | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18253665 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112 | Non-Final OA | — | Pending | May 19, 2023 |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | XIAO, YAN | 1642 | §112 | Final Rejection | 33d | Pending | Mar 11, 2023 |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | 6d | Pending | Feb 15, 2023 |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | KAPUSHOC, STEPHEN THOMAS | 1683 | §103 | Non-Final OA | — | Pending | Sep 12, 2022 |
| 17627210 | TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE | SPENCER, ANDREA LYNNE MORRIS | 1631 | §112 | Non-Final OA | — | Pending | Jan 14, 2022 |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | ALLEN, MARIANNE P | — | §103§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18630379 | Optimized CD3 Antigen Binding Domains | GUSTILO, ESTELLA M | — | §101§112DP | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18414892 | BCMA Monoclonal Antibody-Drug Conjugate | BRISTOL, LYNN ANNE | 1643 | §112DPOther | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18559910 | MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE | WEN, SHARON X | 1641 | §102§103§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | CHATTIN, AMY MARIE | 1643 | §112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18360542 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | HAMA, JOANNE | 1647 | §103Other | Non-Final OA | 42d | Pending | Jul 27, 2023 |
| 18001637 | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPEUTIC | SWIFT, CANDICE LEE | 1657 | §103§112 | Non-Final OA | 28d overdue | Pending | Jul 14, 2023 |
| 18178687 | TREATMENT METHODS USING CTLA-4 AND PD-1 BISPECIFIC ANTIBODIES | VAN DRUFF, SYDNEY | 1643 | §103§112Other | Final Rejection | — | Pending | Mar 06, 2023 |
| 17907683 | STABILIZED IGG4 ANTIBODIES AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | ROGERS, ERIC JASON | 1638 | §112DP | Final Rejection | 3d overdue | Pending | Jun 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial